Navigation Links
Amilpar - Distribution of Interest on Capital Stock
Date:12/29/2009

RIO DE JANEIRO, Dec. 29 /PRNewswire-FirstCall/ -- Amilpar (Bovespa: AMIL3; Bloomberg: AMIL3 BZ and APAR < GO >; Reuters: AMIL3.SA), the largest managed care organization in Brazil, informs its Shareholders that the Board of Directors of the Company, in a meeting held today, approved the payment of Interest on Capital Stock in the gross amount of R$ 0.0168 per common share, corresponding to the total amount of R$ 6.0 million. The payment will be made on April 30, 2010, based on shareholders' position as of December 29, 2009.

Except for exempt shareholders under applicable legislation, the payment of Interest on Capital Stock will have deducted 15% (fifteen per cent) for Income Tax, resulting in net Interest of R$ 0.0143 per common share. The shareholders exempt from Tax Withholding must confirm this status by mailing the corresponding documents to the following address no later than January 5, 2010:

    Amilpar - Relacoes com Investidores (Investor Relations)
    Av. das Americas, 4,200 - Bl. 3 - 4th Floor - Barra da Tijuca
    Rio de Janeiro - RJ - Postal Code 22640-907

The Company will consider the shareholder not tax-exempt if the above- mentioned documents are not received by the aforementioned date.

The Interest on Capital Stock will be attributed to the minimum mandatory dividend relative to the fiscal year ending December 31, 2009 for its net amount, after the deduction of Income Tax, as per Paragraph 7, article 9 of the Brazilian Corporate Law # 9,249/95, and in item V of CVM Deliberation 207/96.

Please note that shares acquired on or after December 30, 2009 will be traded Ex-Interest on Capital Stock.

To access the Notice to Shareholders, visit our website at www.amilpar.com.br/ir

    IR Contact
    Erwin Kleuser
    Investor Relations Officer
    Phone: +55 (21) 3805-1155
    invest@amil.com.br
    www.amilpar.com.br/ir

SOURCE Amilpar


'/>"/>
SOURCE Amilpar
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Amilpar - Relevant Fact
2. Amilpar - Press Release - Commercial Papers
3. Amilpar - Relevant Fact - Public Offer
4. Amilpar - Revenues Grow 8% and Net Income Improves 28% in 3Q09
5. Amilpar - Operating Revenues Grew 9% in the Second Quarter and 11% in the First Half of 2009
6. Amilpar - Revenue Increases 13.4% and Medical Loss Ratio Falls in the First Quarter 2009
7. Amilpar - Revenues Increase by 26.5% and Adjusted Net Income Climbs 28.7% in 2008
8. Amilpar - Notice to Shareholders - Distribution of Interest on Capital Stock
9. Amilpar Revenues Grow 28% in the First 9 Months of 2008 and 4.5% Over Previous Quarter
10. Amilpar Revenues Increase by 32% and EBITDA Doubles in 2007
11. Grubb & Ellis Healthcare REIT II Declares Initial Distribution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , ... February 23, 2017 , ... ... of Justice jointly issued a letter to withdraw previous guidance issued ... their gender identity. The guidance issued in May 2016 by the Obama Administration ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... with a clinician-based audience, will be participating in Rare Disease Day events, hosted ... D.C. In addition, Rare Disease Report, a website, weekly e-newsletter and quarterly publication, ...
(Date:2/23/2017)... , ... February 23, 2017 , ... Hamlin Dental Group ... that they are sponsoring a raffle. Throughout the month of February, patients who visit ... a gift card for a dinner for two at the Cheesecake Factory. , ...
(Date:2/23/2017)... Los Angeles, California (PRWEB) , ... February 23, ... ... for Global Sports Development will host a diverse symposium on “Doping ... School of Law and Sheppard Mullin Richter & Hampton LLP. The symposium will ...
(Date:2/23/2017)... ... 23, 2017 , ... ERT, a global data and technology ... Research, a leading clinical development service provider, has selected ERT’s Trial Oversight suite ... in part to an array of circumstances including the use of multiple data ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 2017 Nevro Corp. (NYSE: NVRO), a global medical ... treatment of chronic pain, today reported financial results for the ... 2016 Accomplishment & Highlights: Achieved ... increase of 228% as reported, over the prior year ... of 612% over the prior year International ...
(Date:2/23/2017)... Calif. , Feb. 23, 2017 ... company focused on the development and commercialization of ... pain, announced that it will release fourth quarter ... Thursday, March 2nd, 2017. AcelRx management will host ... Time (1:30 p.m. Pacific Time) on March 2 ...
(Date:2/23/2017)... , Feb 23, 2017 ... Research and Markets has announced the ... Industry Forecast to 2025" report to their offering. ... of around 1.8% over the next decade to reach approximately $12.8 billion ... estimates and forecasts for all the given segments on global as well ...
Breaking Medicine Technology: